## Supplementary material


### CRISPR-screen

![
**EVOS Fluorescent Microscope Image Capture.**
A. HepG2_lentiV2_Ctrl with no-viral transduction.
B. HepG2_lentiV2 with viral transduction.
<!--  -->
](images/crispr/figure1.png "EVOS Fluorescent Microscope Image Capture"){#fig:sup:crispr:fig1 width="80%"}


![
**Fluorescence-Activated Cell Sorting Gate Setting.**
A. HepG2_UnStained WT.
B. HepG2_lentiV2 with viral transduction.
<!--  -->
](images/crispr/figure2.png "Fluorescence-Activated Cell Sorting Gate Setting"){#fig:sup:crispr:fig2 width="80%"}


![
**Verification of sgRNA cassette and lentiV2 transgene.**
A. 20nt sgRNA cassette was verified in lentiV2 transduced genomic DNA population, 163 bp PCR product obtained, while WT HepG2 didn’t possess the cassette, thus, no PCR product.
B. lentiviral-specific transgene WPRE was verified in lentiV2 transduced genomic DNA population, while no transduced WT didn’t have the transgene, therefore, no 173 bp PCR product observed.
<!--  -->
](images/crispr/figure3.png "Verification of sgRNA cassette and lentiV2 transgene"){#fig:sup:crispr:fig3 width="80%"}


![
<!-- **XXX.** -->
<!--  -->
<!--  -->
](images/crispr/table1.png "Table 1"){#fig:sup:crispr:table1 width="80%"}


![
**Illumina library generation.**
A. Construct for generating illumina libraries.
B. Final illumina library from HS DNA ---showed a single ~285bp peak was generated.
](images/crispr/figure4.png "xxxx"){#fig:sup:crispr:fig4 width="80%"}


### LV603

<!-- LV603:multiplier_pathways:start -->
| Pathway                             | AUC   | FDR      |
|:------------------------------------|:------|:---------|
| IRIS Neutrophil-Resting             | 0.91  | 4.51e-35 |
| SVM Neutrophils                     | 0.98  | 1.43e-09 |
| PID IL8CXCR2 PATHWAY                | 0.81  | 7.04e-03 |
| SIG PIP3 SIGNALING IN B LYMPHOCYTES | 0.77  | 1.95e-02 |

Table: Pathways aligned to LV603. {#tbl:sup:multiplier_pathways:lv603}
<!-- LV603:multiplier_pathways:end -->

<!-- LV603:phenomexcan_traits_assocs:start -->
| Trait description                  | Sample size   | Cases   | FDR      |
|:-----------------------------------|:--------------|:--------|:---------|
| Myeloid White Cell Count           | 173,480       |         | 4.69e-07 |
| Sum Basophil Neutrophil Count      | 173,480       |         | 5.25e-07 |
| Neutrophil Count                   | 173,480       |         | 5.36e-07 |
| Sum Neutrophil Eosinophil Count    | 173,480       |         | 6.06e-07 |
| Granulocyte Count                  | 173,480       |         | 6.60e-07 |
| White Blood Cell Count             | 173,480       |         | 3.35e-06 |
| Neutrophill count                  | 349,856       |         | 1.93e-05 |
| White blood cell (leukocyte) count | 350,470       |         | 2.51e-05 |

Table: Significant trait associations of LV603 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv603}
<!-- LV603:phenomexcan_traits_assocs:end -->

<!-- LV603:emerge_traits_assocs:start -->
| Phecode                     | Trait description   | Sample size   | Cases   | FDR   |
|:----------------------------|:--------------------|:--------------|:--------|:------|
| No significant associations |                     |               |         |       |

Table: Significant trait associations of LV603 in eMERGE. {#tbl:sup:emerge_assocs:lv603}
<!-- LV603:emerge_traits_assocs:end -->


### Gene modules enrichment for lipids gene-sets

<!-- lipids_gene_sets:modules_enriched_increase:start -->
| Gene module   | Lipids gene-set   | Leading edge      | p-value   |
|:--------------|:------------------|:------------------|:----------|
| **LV246**     | increase          | *DGAT2*, *ACACA*  | 0.0035    |
| LV702         | increase          | *ACACA*, *DGAT2*  | 0.0046    |
| **LV607**     | increase          | *ACACA*, *DGAT2*  | 0.0058    |
| LV890         | increase          | *ACACA*, *DGAT2*  | 0.0067    |
| **LV74**      | increase          | *MBTPS1*, *DGAT2* | 0.0078    |
| **LV865**     | increase          | *ACACA*, *DGAT2*  | 0.0092    |
| LV841         | increase          | *ACACA*, *DGAT2*  | 0.0096    |

Table: Gene modules (LVs) nominally enriched for the lipids-increasing gene-set from the CRISPR-screen (*P* < 0.01). LVs significantly aligned with pathways (FDR < 0.05) from the MultiPLIER models are shown in boldface. {#tbl:sup:lipids_crispr:modules_enriched_increase}
<!-- lipids_gene_sets:modules_enriched_increase:end -->


<!-- lipids_gene_sets:modules_enriched_decrease:start -->
| Gene module   | Lipids gene-set   | Leading edge       | p-value   |
|:--------------|:------------------|:-------------------|:----------|
| LV520         | decrease          | *FBXW7*, *TCF7L2*  | 0.0006    |
| LV801         | decrease          | *UBE2J2*, *TCF7L2* | 0.0022    |
| LV512         | decrease          | *FBXW7*, *TCF7L2*  | 0.0025    |
| **LV612**     | decrease          | *PTEN*, *FBXW7*    | 0.0036    |
| LV41          | decrease          | *PCYT2*, *TCF7L2*  | 0.0041    |
| **LV838**     | decrease          | *UBE2J2*, *TCF7L2* | 0.0070    |
| LV302         | decrease          | *TCF7L2*, *PTEN*   | 0.0083    |
| LV959         | decrease          | *TCF7L2*, *PTEN*   | 0.0092    |

Table: Gene modules (LVs) nominally enriched for the lipids-decreasing gene-set from the CRISPR-screen (*P* < 0.01). LVs significantly aligned with pathways (FDR < 0.05) from the MultiPLIER models are shown in boldface. {#tbl:sup:lipids_crispr:modules_enriched_decrease}
<!-- lipids_gene_sets:modules_enriched_decrease:end -->


### LV246

<!-- LV246:multiplier_pathways:start -->
| Pathway                                                        | AUC   | FDR      |
|:---------------------------------------------------------------|:------|:---------|
| REACTOME FATTY ACID TRIACYLGLYCEROL AND KETONE BODY METABOLISM | 0.89  | 3.97e-16 |
| REACTOME METABOLISM OF LIPIDS AND LIPOPROTEINS                 | 0.67  | 1.14e-08 |
| REACTOME TRIGLYCERIDE BIOSYNTHESIS                             | 0.86  | 6.52e-04 |
| KEGG PYRUVATE METABOLISM                                       | 0.82  | 2.66e-03 |
| KEGG PROPANOATE METABOLISM                                     | 0.83  | 4.27e-03 |

Table: Pathways aligned to LV246 from the MultiPLIER models. {#tbl:sup:multiplier_pathways:lv246}
<!-- LV246:multiplier_pathways:end -->

<!-- LV246:phenomexcan_traits_assocs:start -->
| Trait description                                        | Sample size   | Cases   | FDR      |
|:---------------------------------------------------------|:--------------|:--------|:---------|
| CH2DB NMR                                                | 24,154        |         | 1.53e-12 |
| High cholesterol (self-reported)                         | 361,141       | 43,957  | 9.89e-07 |
| Ankle spacing width                                      | 206,589       |         | 2.51e-05 |
| Ankle spacing width (right)                              | 114,614       |         | 1.09e-04 |
| HDL Cholesterol NMR                                      | 19,270        |         | 2.96e-04 |
| Cholesterol lowering medication                          | 193,148       | 24,247  | 3.05e-04 |
| Ankle spacing width (left)                               | 114,630       |         | 6.36e-04 |
| Fasting Glucose                                          | 46,186        |         | 2.24e-03 |
| Cholesterol lowering medication                          | 165,340       | 38,057  | 7.96e-03 |
| Pulse rate, automated reading                            | 340,162       |         | 1.01e-02 |
| Recent easy annoyance or irritability                    | 117,483       |         | 1.21e-02 |
| Treatment/medication code: simvastatin                   | 361,141       | 40,921  | 1.30e-02 |
| Pulse rate                                               | 118,850       |         | 1.40e-02 |
| Mean platelet (thrombocyte) volume                       | 350,470       |         | 1.60e-02 |
| Duration of moderate activity                            | 268,826       |         | 1.96e-02 |
| LDL Cholesterol NMR                                      | 13,527        |         | 2.26e-02 |
| Red blood cell (erythrocyte) distribution width          | 350,473       |         | 2.32e-02 |
| Intra-ocular pressure, corneal-compensated (right)       | 76,630        |         | 3.05e-02 |
| Heel bone mineral density (BMD) (right)                  | 114,552       |         | 3.17e-02 |
| Triglycerides NMR                                        | 21,559        |         | 4.02e-02 |
| Heel quantitative ultrasound index, direct entry (right) | 114,614       |         | 4.34e-02 |
| Heel bone mineral density T-score, automated (right)     | 114,614       |         | 4.34e-02 |

Table: Significant trait associations of LV246 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv246}
<!-- LV246:phenomexcan_traits_assocs:end -->

<!-- LV246:emerge_traits_assocs:start -->
| Phecode   | Trait description          | Sample size   | Cases   | FDR      |
|:----------|:---------------------------|:--------------|:--------|:---------|
| 276.41    | Acidosis                   | 41,838        | 1,526   | 2.40e-03 |
| 276.4     | Acid-base balance disorder | 42,005        | 1,693   | 2.97e-03 |

Table: Significant trait associations of LV246 in eMERGE. {#tbl:sup:emerge_assocs:lv246}
<!-- LV246:emerge_traits_assocs:end -->


### LV116

<!-- LV116:multiplier_pathways:start -->
| Pathway                                              | AUC   | FDR      |
|:-----------------------------------------------------|:------|:---------|
| REACTOME INTERFERON SIGNALING                        | 0.84  | 3.48e-09 |
| SVM Macrophages M1                                   | 0.92  | 2.09e-05 |
| REACTOME INTERFERON ALPHA BETA SIGNALING             | 0.94  | 3.36e-05 |
| REACTOME CYTOKINE SIGNALING IN IMMUNE SYSTEM         | 0.67  | 1.53e-04 |
| IRIS DendriticCell-LPSstimulated                     | 0.65  | 1.09e-03 |
| KEGG CYTOSOLIC DNA SENSING PATHWAY                   | 0.84  | 3.22e-03 |
| REACTOME NEGATIVE REGULATORS OF RIG I MDA5 SIGNALING | 0.81  | 1.61e-02 |

Table: Pathways aligned to LV116 from the MultiPLIER models. {#tbl:sup:multiplier_pathways:lv116}
<!-- LV116:multiplier_pathways:end -->


### LV931

![
**Cell types for LV931.**
<!--  -->
](images/lvs_analysis/lv931/lv931-cell_types.svg "Cell types for LV931"){#fig:sup:lv931 width="80%"}


<!-- LV931:multiplier_pathways:start -->
| Pathway          | AUC   | FDR      |
|:-----------------|:------|:---------|
| MIPS SPLICEOSOME | 0.63  | 3.13e-02 |
| PID TGFBRPATHWAY | 0.71  | 3.99e-02 |

Table: Pathways aligned to LV931 from the MultiPLIER models. {#tbl:sup:multiplier_pathways:lv931}
<!-- LV931:multiplier_pathways:end -->


### LV66

![
**Cell types for LV66.**
<!--  -->
](images/lvs_analysis/lv66/lv66-cell_types.svg "Cell types for LV66"){#fig:sup:lv66 width="80%"}


### Cluster-specific and general transcriptional processes associated with disease

![
**Cluster-specific and general transcriptional processes associated with disease using novel LVs.**
The plot shows a submatrix of $\hat{\mathbf{M}}$ for the main trait clusters at $k$=29, considering only LVs (rows) that are not aligned with any pathway.
Standardized values from -6 (lighter color) to 21 (darker color).
](images/clustering/global_clustermap-novel-plain.svg "Heatmap with novel gene modules and traits"){#fig:sup:clustering:novel:heatmap width="100%"}



### LV928

![
**Cell types for LV928.**
<!--  -->
](images/lvs_analysis/lv928/lv928-cell_types.svg "Cell types for LV928"){#fig:sup:lv928 width="80%"}


### LV30

![
**Cell types for LV30.**
<!--  -->
](images/lvs_analysis/lv30/lv30-cell_types.svg "Cell types for LV30"){#fig:sup:lv30 width="80%"}


### LV730

![
**Cell types for LV730.**
<!--  -->
](images/lvs_analysis/lv730/lv730-cell_types.svg "Cell types for LV730"){#fig:sup:lv730 width="80%"}


### LV598

![
**Cell types for LV598.**
<!--  -->
](images/lvs_analysis/lv598/lv598-cell_types.svg "Cell types for LV598"){#fig:sup:lv598 width="80%"}

<!-- LV598:phenomexcan_traits_assocs:start -->
| Trait description           | Sample size   | Cases   | Partition/cluster number   | p-value (adjusted)   |
|:----------------------------|:--------------|:--------|:---------------------------|:---------------------|
| 6mm strong meridian (right) | 66,256        |         | 29 / 10                    | 4.13e-07             |
| 6mm weak meridian (right)   | 66,256        |         | 29 / 10                    | 2.63e-06             |
| 6mm strong meridian (left)  | 65,551        |         | 29 / 10                    | 3.13e-06             |
| 3mm strong meridian (left)  | 75,398        |         | 29 / 10                    | 3.24e-06             |
| 6mm weak meridian (left)    | 65,551        |         | 29 / 10                    | 1.53e-05             |
| 3mm weak meridian (left)    | 75,398        |         | 29 / 10                    | 2.00e-05             |
| 3mm strong meridian (right) | 75,410        |         | 29 / 10                    | 3.70e-05             |
| 3mm weak meridian (right)   | 75,410        |         | 29 / 10                    | 4.81e-05             |

Table: Significant trait associations of LV598 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv598}
<!-- LV598:phenomexcan_traits_assocs:end -->

<!-- DISABLED LV598:emerge_traits_assocs:start -->
<!-- DISABLED LV598:emerge_traits_assocs:end -->


### LV155

![
**Cell types for LV155.**
<!--  -->
](images/lvs_analysis/lv155/lv155-cell_types.svg "Cell types for LV155"){#fig:sup:lv155 width="80%"}

<!-- LV155:phenomexcan_traits_assocs:start -->
| Trait description                                                      | Sample size   | Cases   | Partition/cluster number   | p-value (adjusted)   |
|:-----------------------------------------------------------------------|:--------------|:--------|:---------------------------|:---------------------|
| Non-cancer illness code, self-reported: hypothyroidism/myxoedema       | 361,141       | 17,574  | 29 / 13                    | 2.01e-03             |
| Non-cancer illness code, self-reported: hyperthyroidism/thyrotoxicosis | 361,141       | 2,730   | 29 / 13                    | 1.29e-02             |
| Treatment/medication code: levothyroxine sodium                        | 361,141       | 14,689  | 29 / 13                    | 1.41e-02             |

Table: Significant trait associations of LV155 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv155}
<!-- LV155:phenomexcan_traits_assocs:end -->

<!-- LV155:emerge_traits_assocs:start -->
| Phecode   | Trait description       | Sample size   | Cases   | p-value (adjusted)   |
|:----------|:------------------------|:--------------|:--------|:---------------------|
| 244.2     | Acquired hypothyroidism | 45,839        | 1,155   | 2.19e-02             |
| 427.9     | Palpitations            | 35,214        | 6,092   | 4.43e-02             |

Table: Significant trait associations of LV155 in eMERGE. {#tbl:sup:emerge_assocs:lv155}
<!-- LV155:emerge_traits_assocs:end -->


### LV844

![
**Cell types for LV844.**
<!--  -->
<!-- `Note`{.red} "Cell types from brain" come from [@doi:10.1073/pnas.1516645112], treated with different chemichals; I don't have enough information to separate cell types. -->
<!--  -->
](images/lvs_analysis/lv844/lv844-cell_types.svg "Cell types for LV844"){#fig:sup:lv844 width="80%"}

<!-- LV844:phenomexcan_traits_assocs:start -->
| Trait description                                                                         | Sample size   | Cases   | Partition/cluster number   | p-value (adjusted)   |
|:------------------------------------------------------------------------------------------|:--------------|:--------|:---------------------------|:---------------------|
| Rheumatoid Arthritis                                                                      | 80,799        | 19,234  | 29 / 26                    | 4.27e-57             |
| Non-cancer illness code, self-reported: malabsorption/coeliac disease                     | 361,141       | 1,587   | 29 / 8                     | 4.83e-43             |
| Coeliac disease                                                                           | 361,194       | 842     | 29 / 8                     | 4.76e-41             |
| Diagnoses - main ICD10: K90 Intestinal malabsorption                                      | 361,194       | 922     | 29 / 8                     | 1.41e-39             |
| Started insulin within one year diagnosis of diabetes                                     | 16,415        | 1,999   | 29 / 13                    | 1.78e-37             |
| Systemic Lupus Erythematosus                                                              | 23,210        | 7,219   | 29 / 26                    | 1.41e-34             |
| Age diabetes diagnosed                                                                    | 16,166        |         | 29 / 13                    | 3.93e-34             |
| Never eat eggs, dairy, wheat, sugar: Wheat products                                       | 359,777       | 9,573   | 29 / 13                    | 2.78e-31             |
| Non-cancer illness code, self-reported: hyperthyroidism/thyrotoxicosis                    | 361,141       | 2,730   | 29 / 13                    | 6.08e-30             |
| Treatment/medication code: insulin product                                                | 361,141       | 3,545   | 29 / 13                    | 3.05e-25             |
| Medication for cholesterol, blood pressure, diabetes, or take exogenous hormones: Insulin | 193,148       | 1,476   | 29 / 13                    | 4.63e-23             |
| Medication for cholesterol, blood pressure or diabetes: Insulin                           | 165,340       | 2,248   | 29 / 13                    | 1.92e-20             |
| Non-cancer illness code, self-reported: hypothyroidism/myxoedema                          | 361,141       | 17,574  | 29 / 13                    | 4.96e-20             |
| Treatment/medication code: levothyroxine sodium                                           | 361,141       | 14,689  | 29 / 13                    | 4.01e-19             |
| Non-cancer illness code, self-reported: psoriasis                                         | 361,141       | 4,192   | 29 / 13                    | 9.28e-16             |

Table: Significant trait associations of LV844 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv844}
<!-- LV844:phenomexcan_traits_assocs:end -->

<!-- LV844:emerge_traits_assocs:start -->
| Phecode   | Trait description                                             | Sample size   | Cases   | p-value (adjusted)   |
|:----------|:--------------------------------------------------------------|:--------------|:--------|:---------------------|
| 714.1     | Rheumatoid arthritis                                          | 49,453        | 2,541   | 8.22e-09             |
| 250.1     | Type 1 diabetes                                               | 42,723        | 2,450   | 2.54e-08             |
| 714       | Rheumatoid arthritis and other inflammatory polyarthropathies | 50,215        | 3,303   | 5.06e-07             |
| 440       | Atherosclerosis                                               | 47,471        | 4,993   | 3.15e-03             |
| 578.8     | Hemorrhage of rectum and anus                                 | 47,545        | 1,991   | 3.15e-03             |
| 585.32    | End stage renal disease                                       | 43,309        | 1,842   | 4.38e-03             |
| 440.2     | Atherosclerosis of the extremities                            | 45,524        | 3,046   | 5.00e-03             |
| 514.2     | Solitary pulmonary nodule                                     | 50,389        | 2,270   | 6.16e-03             |
| 444       | Arterial embolism and thrombosis                              | 43,378        | 900     | 1.36e-02             |
| 558       | Noninfectious gastroenteritis                                 | 40,177        | 3,191   | 2.94e-02             |
| 747.11    | Cardiac shunt/ heart septal defect                            | 58,364        | 1,037   | 3.60e-02             |
| 585       | Renal failure                                                 | 51,437        | 9,970   | 3.87e-02             |
| 443.9     | Peripheral vascular disease, unspecified                      | 46,926        | 4,448   | 4.43e-02             |

Table: Significant trait associations of LV844 in eMERGE. {#tbl:sup:emerge_assocs:lv844}
<!-- LV844:emerge_traits_assocs:end -->


### LV57

![
**Cell types for LV57.**
<!--  -->
<!--  -->
](images/lvs_analysis/lv57/lv57-cell_types.svg "Cell types for LV57"){#fig:sup:lv57 width="80%"}

<!-- LV57:phenomexcan_traits_assocs:start -->
| Trait description                                                                         | Sample size   | Cases   | Partition/cluster number   | p-value (adjusted)   |
|:------------------------------------------------------------------------------------------|:--------------|:--------|:---------------------------|:---------------------|
| Non-cancer illness code, self-reported: hypothyroidism/myxoedema                          | 361,141       | 17,574  | 29 / 13                    | 1.17e-24             |
| Treatment/medication code: levothyroxine sodium                                           | 361,141       | 14,689  | 29 / 13                    | 6.07e-23             |
| Non-cancer illness code, self-reported: hyperthyroidism/thyrotoxicosis                    | 361,141       | 2,730   | 29 / 13                    | 1.16e-06             |
| Started insulin within one year diagnosis of diabetes                                     | 16,415        | 1,999   | 29 / 13                    | 8.17e-05             |
| Treatment/medication code: insulin product                                                | 361,141       | 3,545   | 29 / 13                    | 6.33e-04             |
| Medication for cholesterol, blood pressure, diabetes, or take exogenous hormones: Insulin | 193,148       | 1,476   | 29 / 13                    | 1.13e-03             |
| Medication for cholesterol, blood pressure or diabetes: Insulin                           | 165,340       | 2,248   | 29 / 13                    | 4.50e-03             |

Table: Significant trait associations of LV57 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv57}
<!-- LV57:phenomexcan_traits_assocs:end -->

<!-- LV57:emerge_traits_assocs:start -->
| Phecode   | Trait description                                             | Sample size   | Cases   | p-value (adjusted)   |
|:----------|:--------------------------------------------------------------|:--------------|:--------|:---------------------|
| 244       | Hypothyroidism                                                | 54,404        | 9,720   | 3.97e-09             |
| 244.4     | Hypothyroidism NOS                                            | 53,968        | 9,284   | 3.97e-09             |
| 279       | Disorders involving the immune mechanism                      | 56,771        | 3,309   | 4.93e-03             |
| 514.2     | Solitary pulmonary nodule                                     | 50,389        | 2,270   | 1.19e-02             |
| 714       | Rheumatoid arthritis and other inflammatory polyarthropathies | 50,215        | 3,303   | 1.68e-02             |
| 452.2     | Deep vein thrombosis [DVT]                                    | 38,791        | 2,131   | 4.37e-02             |

Table: Significant trait associations of LV57 in eMERGE. {#tbl:sup:emerge_assocs:lv57}
<!-- LV57:emerge_traits_assocs:end -->


### LV54

![
**Cell types for LV54.**
<!--  -->
<!--  -->
](images/lvs_analysis/lv54/lv54-cell_types.svg "Cell types for LV54"){#fig:sup:lv54 width="80%"}

<!-- LV54:phenomexcan_traits_assocs:start -->
| Trait description                                                                         | Sample size   | Cases   | Partition/cluster number   | p-value (adjusted)   |
|:------------------------------------------------------------------------------------------|:--------------|:--------|:---------------------------|:---------------------|
| Diagnoses - main ICD10: K90 Intestinal malabsorption                                      | 361,194       | 922     | 29 / 8                     | 5.09e-25             |
| Coeliac disease                                                                           | 361,194       | 842     | 29 / 8                     | 7.77e-25             |
| Never eat eggs, dairy, wheat, sugar: Wheat products                                       | 359,777       | 9,573   | 29 / 13                    | 6.33e-23             |
| Systemic Lupus Erythematosus                                                              | 23,210        | 7,219   | 29 / 26                    | 1.32e-22             |
| Started insulin within one year diagnosis of diabetes                                     | 16,415        | 1,999   | 29 / 13                    | 3.84e-20             |
| Non-cancer illness code, self-reported: hyperthyroidism/thyrotoxicosis                    | 361,141       | 2,730   | 29 / 13                    | 9.59e-19             |
| Treatment/medication code: insulin product                                                | 361,141       | 3,545   | 29 / 13                    | 5.07e-18             |
| Age diabetes diagnosed                                                                    | 16,166        |         | 29 / 13                    | 1.28e-17             |
| Non-cancer illness code, self-reported: malabsorption/coeliac disease                     | 361,141       | 1,587   | 29 / 8                     | 1.36e-14             |
| Medication for cholesterol, blood pressure or diabetes: Insulin                           | 165,340       | 2,248   | 29 / 13                    | 8.67e-14             |
| Non-cancer illness code, self-reported: psoriasis                                         | 361,141       | 4,192   | 29 / 13                    | 2.61e-13             |
| Rheumatoid Arthritis                                                                      | 80,799        | 19,234  | 29 / 26                    | 3.11e-13             |
| Medication for cholesterol, blood pressure, diabetes, or take exogenous hormones: Insulin | 193,148       | 1,476   | 29 / 13                    | 3.89e-12             |
| Treatment/medication code: levothyroxine sodium                                           | 361,141       | 14,689  | 29 / 13                    | 5.92e-10             |
| Non-cancer illness code, self-reported: hypothyroidism/myxoedema                          | 361,141       | 17,574  | 29 / 13                    | 3.31e-08             |

Table: Significant trait associations of LV54 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv54}
<!-- LV54:phenomexcan_traits_assocs:end -->

<!-- LV54:emerge_traits_assocs:start -->
| Phecode   | Trait description                                             | Sample size   | Cases   | p-value (adjusted)   |
|:----------|:--------------------------------------------------------------|:--------------|:--------|:---------------------|
| 250.1     | Type 1 diabetes                                               | 42,723        | 2,450   | 2.04e-13             |
| 244       | Hypothyroidism                                                | 54,404        | 9,720   | 5.10e-06             |
| 244.4     | Hypothyroidism NOS                                            | 53,968        | 9,284   | 5.37e-06             |
| 695       | Erythematous conditions                                       | 48,347        | 4,210   | 4.25e-05             |
| 714       | Rheumatoid arthritis and other inflammatory polyarthropathies | 50,215        | 3,303   | 3.06e-04             |
| 440       | Atherosclerosis                                               | 47,471        | 4,993   | 8.88e-04             |
| 585       | Renal failure                                                 | 51,437        | 9,970   | 3.40e-03             |
| 585.32    | End stage renal disease                                       | 43,309        | 1,842   | 3.64e-03             |
| 585.33    | Chronic Kidney Disease, Stage III                             | 46,279        | 4,812   | 3.64e-03             |
| 285.2     | Anemia of chronic disease                                     | 39,673        | 2,606   | 7.62e-03             |
| 415.1     | Acute pulmonary heart disease                                 | 49,887        | 1,857   | 8.67e-03             |
| 285.21    | Anemia in chronic kidney disease                              | 38,616        | 1,549   | 1.16e-02             |
| 743       | Osteoporosis, osteopenia and pathological fracture            | 55,165        | 11,990  | 1.31e-02             |
| 415.11    | Pulmonary embolism and infarction, acute                      | 49,867        | 1,837   | 1.39e-02             |
| 577       | Diseases of pancreas                                          | 60,538        | 1,795   | 1.42e-02             |
| 585.1     | Acute renal failure                                           | 46,803        | 5,336   | 1.51e-02             |
| 195       | Cancer, suspected or other                                    | 50,040        | 2,250   | 1.52e-02             |
| 440.2     | Atherosclerosis of the extremities                            | 45,524        | 3,046   | 1.89e-02             |
| 714.1     | Rheumatoid arthritis                                          | 49,453        | 2,541   | 3.18e-02             |
| 458.9     | Hypotension NOS                                               | 50,150        | 3,241   | 3.32e-02             |

Table: Significant trait associations of LV54 in eMERGE. {#tbl:sup:emerge_assocs:lv54}
<!-- LV54:emerge_traits_assocs:end -->


### LV847

![
**Cell types for LV847.**
<!--  -->
<!--  -->
](images/lvs_analysis/lv847/lv847-cell_types.svg "Cell types for LV847"){#fig:sup:lv847 width="80%"}

<!-- LV847:phenomexcan_traits_assocs:start -->
| Trait description                                                                                           | Sample size   | Cases   | Partition/cluster number   | p-value (adjusted)   |
|:------------------------------------------------------------------------------------------------------------|:--------------|:--------|:---------------------------|:---------------------|
| Medication for cholesterol, blood pressure, diabetes, or take exogenous hormones: Blood pressure medication | 193,148       | 33,519  | 29 / 17                    | 1.95e-18             |
| Vascular/heart problems diagnosed by doctor: None of the above                                              | 360,420       | 253,565 | 29 / 17                    | 4.07e-15             |
| Vascular/heart problems diagnosed by doctor: High blood pressure                                            | 360,420       | 97,139  | 29 / 17                    | 6.99e-14             |
| Non-cancer illness code, self-reported: hypertension                                                        | 361,141       | 93,560  | 29 / 17                    | 1.48e-13             |
| Treatment/medication code: bendroflumethiazide                                                              | 361,141       | 20,196  | 29 / 17                    | 1.41e-08             |
| Medication for cholesterol, blood pressure or diabetes: Blood pressure medication                           | 165,340       | 40,987  | 29 / 17                    | 1.47e-07             |
| Medication for cholesterol, blood pressure, diabetes, or take exogenous hormones: None of the above         | 193,148       | 133,338 | 29 / 17                    | 1.55e-06             |
| Diastolic blood pressure, automated reading                                                                 | 340,162       |         | 29 / 17                    | 3.76e-06             |
| Medication for cholesterol, blood pressure or diabetes: None of the above                                   | 165,340       | 110,372 | 29 / 17                    | 6.36e-06             |

Table: Significant trait associations of LV847 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv847}
<!-- LV847:phenomexcan_traits_assocs:end -->

<!-- LV847:emerge_traits_assocs:start -->
| Phecode   | Trait description                                              | Sample size   | Cases   | p-value (adjusted)   |
|:----------|:---------------------------------------------------------------|:--------------|:--------|:---------------------|
| 585.32    | End stage renal disease                                        | 43,309        | 1,842   | 1.88e-08             |
| 442.1     | Aortic aneurysm                                                | 45,589        | 3,111   | 5.23e-06             |
| 411.3     | Angina pectoris                                                | 43,503        | 4,382   | 2.14e-05             |
| 415.11    | Pulmonary embolism and infarction, acute                       | 49,867        | 1,837   | 5.13e-05             |
| 416       | Cardiomegaly                                                   | 53,289        | 5,259   | 6.50e-05             |
| 415.1     | Acute pulmonary heart disease                                  | 49,887        | 1,857   | 7.28e-05             |
| 411       | Ischemic Heart Disease                                         | 54,275        | 15,154  | 5.49e-04             |
| 401.2     | Hypertensive heart and/or renal disease                        | 30,405        | 6,253   | 1.28e-03             |
| 519       | Other diseases of respiratory system, not elsewhere classified | 56,909        | 2,056   | 1.28e-03             |
| 411.8     | Other chronic ischemic heart disease, unspecified              | 44,123        | 5,002   | 1.42e-03             |
| 427.6     | Premature beats                                                | 31,575        | 2,453   | 5.65e-03             |
| 687.1     | Rash and other nonspecific skin eruption                       | 47,039        | 4,964   | 9.88e-03             |
| 185       | Cancer of prostate                                             | 52,630        | 2,815   | 1.03e-02             |
| 591       | Urinary tract infection                                        | 49,727        | 10,016  | 1.34e-02             |
| 442.11    | Abdominal aortic aneurysm                                      | 44,531        | 2,053   | 2.08e-02             |
| 427.21    | Atrial fibrillation                                            | 37,743        | 8,621   | 2.26e-02             |
| 389.1     | Sensorineural hearing loss                                     | 53,672        | 4,318   | 2.73e-02             |
| 427.2     | Atrial fibrillation and flutter                                | 37,934        | 8,812   | 4.50e-02             |

Table: Significant trait associations of LV847 in eMERGE. {#tbl:sup:emerge_assocs:lv847}
<!-- LV847:emerge_traits_assocs:end -->


### LV136

![
**Cell types for LV136.**
<!--  -->
Pulmonary microvascular endothelial cells were exposed to hypoxia for 24 hours or more [@url:https://www.ncbi.nlm.nih.gov/bioproject/PRJNA232177];
](images/lvs_analysis/lv136/lv136-cell_types.svg "Cell types for LV136"){#fig:sup:lv136 width="80%"}

<!-- LV136:phenomexcan_traits_assocs:start -->
| Trait description                                                          | Sample size   | Cases   | Partition/cluster number   | p-value (adjusted)   |
|:---------------------------------------------------------------------------|:--------------|:--------|:---------------------------|:---------------------|
| 3mm strong meridian (right)                                                | 75,410        |         | 29 / 10                    | 9.19e-11             |
| 6mm strong meridian (left)                                                 | 65,551        |         | 29 / 10                    | 2.06e-09             |
| 6mm strong meridian (right)                                                | 66,256        |         | 29 / 10                    | 2.38e-09             |
| 3mm strong meridian (left)                                                 | 75,398        |         | 29 / 10                    | 1.34e-08             |
| 3mm weak meridian (right)                                                  | 75,410        |         | 29 / 10                    | 1.67e-08             |
| Coronary Artery Disease                                                    | 184,305       | 60,801  | 29 / 11                    | 1.67e-08             |
| 6mm weak meridian (right)                                                  | 66,256        |         | 29 / 10                    | 3.21e-08             |
| 3mm weak meridian (left)                                                   | 75,398        |         | 29 / 10                    | 5.20e-08             |
| 6mm weak meridian (left)                                                   | 65,551        |         | 29 / 10                    | 1.21e-07             |
| Coronary atherosclerosis                                                   | 361,194       | 14,334  | 29 / 14                    | 3.90e-06             |
| Ischaemic heart disease, wide definition                                   | 361,194       | 20,857  | 29 / 14                    | 7.22e-06             |
| Vascular/heart problems diagnosed by doctor: Heart attack                  | 360,420       | 8,288   | 29 / 14                    | 2.93e-04             |
| Myocardial infarction                                                      | 361,194       | 7,018   | 29 / 14                    | 6.33e-04             |
| Myocardial infarction, strict                                              | 361,194       | 7,018   | 29 / 14                    | 6.33e-04             |
| Diagnoses - main ICD10: I21 Acute myocardial infarction                    | 361,194       | 5,948   | 29 / 14                    | 9.92e-04             |
| Non-cancer illness code, self-reported: heart attack/myocardial infarction | 361,141       | 8,239   | 29 / 14                    | 1.40e-03             |
| Major coronary heart disease event excluding revascularizations            | 361,194       | 10,157  | 29 / 14                    | 1.85e-02             |
| Major coronary heart disease event                                         | 361,194       | 10,157  | 29 / 14                    | 1.85e-02             |
| Fasting Insulin                                                            | 38,238        |         | 29 / 11                    | 3.85e-02             |

Table: Significant trait associations of LV136 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv136}
<!-- LV136:phenomexcan_traits_assocs:end -->

<!-- LV136:emerge_traits_assocs:start -->
| Phecode   | Trait description            | Sample size   | Cases   | p-value (adjusted)   |
|:----------|:-----------------------------|:--------------|:--------|:---------------------|
| 747.1     | Cardiac congenital anomalies | 59,198        | 1,871   | 4.71e-02             |
| 411.4     | Coronary atherosclerosis     | 52,836        | 13,715  | 4.80e-02             |

Table: Significant trait associations of LV136 in eMERGE. {#tbl:sup:emerge_assocs:lv136}
<!-- LV136:emerge_traits_assocs:end -->


### LV93

![
**Cell types for LV93.**
<!--  -->
](images/lvs_analysis/lv93/lv93-cell_types.svg "Cell types for LV93"){#fig:sup:lv93 width="80%"}

<!-- LV93:phenomexcan_traits_assocs:start -->
| Trait description   | Sample size   | Cases   | Partition/cluster number   | p-value (adjusted)   |
|:--------------------|:--------------|:--------|:---------------------------|:---------------------|
| CH2DB NMR           | 24,154        |         | 29 / 16                    | 9.61e-24             |
| Chronotype          | 128,266       |         | 29 / 16                    | 1.17e-03             |
| HDL Cholesterol NMR | 19,270        |         | 29 / 16                    | 2.99e-03             |

Table: Significant trait associations of LV93 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv93}
<!-- LV93:phenomexcan_traits_assocs:end -->

<!-- LV93:emerge_traits_assocs:start -->
| Phecode   | Trait description                  | Sample size   | Cases   | p-value (adjusted)   |
|:----------|:-----------------------------------|:--------------|:--------|:---------------------|
| 208       | Benign neoplasm of colon           | 55,694        | 8,597   | 6.21e-03             |
| 440.2     | Atherosclerosis of the extremities | 45,524        | 3,046   | 1.31e-02             |
| 444       | Arterial embolism and thrombosis   | 43,378        | 900     | 4.06e-02             |

Table: Significant trait associations of LV93 in eMERGE. {#tbl:sup:emerge_assocs:lv93}
<!-- LV93:emerge_traits_assocs:end -->


### LV206

![
**Cell types for LV206.**
<!--  -->
](images/lvs_analysis/lv206/lv206-cell_types.svg "Cell types for LV206"){#fig:sup:lv206 width="80%"}

<!-- LV206:phenomexcan_traits_assocs:start -->
| Trait description   | Sample size   | Cases   | Partition/cluster number   | p-value (adjusted)   |
|:--------------------|:--------------|:--------|:---------------------------|:---------------------|
| CH2DB NMR           | 24,154        |         | 29 / 16                    | 7.67e-21             |
| HDL Cholesterol NMR | 19,270        |         | 29 / 16                    | 6.46e-03             |

Table: Significant trait associations of LV206 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv206}
<!-- LV206:phenomexcan_traits_assocs:end -->

<!-- LV206:emerge_traits_assocs:start -->
| Phecode   | Trait description            | Sample size   | Cases   | p-value (adjusted)   |
|:----------|:-----------------------------|:--------------|:--------|:---------------------|
| 458       | Hypotension                  | 51,341        | 4,432   | 1.41e-02             |
| 286.9     | Abnormal coagulation profile | 48,006        | 800     | 1.54e-02             |
| 458.9     | Hypotension NOS              | 50,150        | 3,241   | 1.58e-02             |
| 428.2     | Heart failure NOS            | 48,178        | 3,584   | 1.65e-02             |

Table: Significant trait associations of LV206 in eMERGE. {#tbl:sup:emerge_assocs:lv206}
<!-- LV206:emerge_traits_assocs:end -->


### LV260

![
**Cell types for LV260.**
<!--  -->
](images/lvs_analysis/lv260/lv260-cell_types.svg "Cell types for LV260"){#fig:sup:lv260 width="80%"}

<!-- LV260:phenomexcan_traits_assocs:start -->
| Trait description   | Sample size   | Cases   | Partition/cluster number   | p-value (adjusted)   |
|:--------------------|:--------------|:--------|:---------------------------|:---------------------|
| CH2DB NMR           | 24,154        |         | 29 / 16                    | 5.96e-17             |
| HDL Cholesterol NMR | 19,270        |         | 29 / 16                    | 2.37e-02             |

Table: Significant trait associations of LV260 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv260}
<!-- LV260:phenomexcan_traits_assocs:end -->

<!-- LV260:emerge_traits_assocs:start -->
| Phecode   | Trait description   | Sample size   | Cases   | p-value (adjusted)   |
|:----------|:--------------------|:--------------|:--------|:---------------------|
| 427.6     | Premature beats     | 31,575        | 2,453   | 2.85e-02             |
| 426.3     | Bundle branch block | 31,827        | 2,705   | 4.80e-02             |

Table: Significant trait associations of LV260 in eMERGE. {#tbl:sup:emerge_assocs:lv260}
<!-- LV260:emerge_traits_assocs:end -->


### LV21

![
**Cell types for LV21.**
<!--  -->
](images/lvs_analysis/lv21/lv21-cell_types.svg "Cell types for LV21"){#fig:sup:lv21 width="80%"}

<!-- LV21:phenomexcan_traits_assocs:start -->
| Trait description   | Sample size   | Cases   | Partition/cluster number   | p-value (adjusted)   |
|:--------------------|:--------------|:--------|:---------------------------|:---------------------|
| Alzheimers Disease  | 54,162        | 17,008  | 29 / 16                    | 1.64e-19             |
| LDL Cholesterol NMR | 13,527        |         | 29 / 16                    | 1.18e-04             |
| Triglycerides NMR   | 21,559        |         | 29 / 16                    | 2.19e-02             |

Table: Significant trait associations of LV21 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv21}
<!-- LV21:phenomexcan_traits_assocs:end -->

<!-- LV21:emerge_traits_assocs:start -->
| Phecode   | Trait description        | Sample size   | Cases   | p-value (adjusted)   |
|:----------|:-------------------------|:--------------|:--------|:---------------------|
| 573       | Other disorders of liver | 47,826        | 2,524   | 1.37e-02             |
| 577       | Diseases of pancreas     | 60,538        | 1,795   | 2.15e-02             |

Table: Significant trait associations of LV21 in eMERGE. {#tbl:sup:emerge_assocs:lv21}
<!-- LV21:emerge_traits_assocs:end -->


### LV5

![
**Cell types for LV5.**
<!--  -->
](images/lvs_analysis/lv5/lv5-cell_types.svg "Cell types for LV5"){#fig:sup:lv5 width="80%"}

<!-- LV5:phenomexcan_traits_assocs:start -->
| Trait description                                                                      | Sample size   | Cases   | Partition/cluster number   | p-value (adjusted)   |
|:---------------------------------------------------------------------------------------|:--------------|:--------|:---------------------------|:---------------------|
| LDL Cholesterol NMR                                                                    | 13,527        |         | 29 / 16                    | 1.78e-04             |
| Triglycerides NMR                                                                      | 21,559        |         | 29 / 16                    | 5.00e-04             |
| Alzheimers Disease                                                                     | 54,162        | 17,008  | 29 / 16                    | 3.06e-03             |
| Ever had prolonged feelings of sadness or depression                                   | 117,763       | 64,374  | 29 / 27                    | 8.69e-03             |
| Substances taken for depression: Medication prescribed to you (for at least two weeks) | 117,763       | 28,351  | 29 / 27                    | 1.03e-02             |
| Recent feelings of depression                                                          | 117,656       |         | 29 / 27                    | 1.32e-02             |
| Ever contemplated self-harm                                                            | 117,610       |         | 29 / 27                    | 1.89e-02             |
| Recent lack of interest or pleasure in doing things                                    | 117,757       |         | 29 / 27                    | 2.08e-02             |
| Amount of alcohol drunk on a typical drinking day                                      | 108,256       |         | 29 / 27                    | 3.50e-02             |
| Ever sought or received professional help for mental distress                          | 117,677       | 46,020  | 29 / 27                    | 3.92e-02             |
| General happiness                                                                      | 117,442       |         | 29 / 27                    | 4.74e-02             |

Table: Significant trait associations of LV5 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv5}
<!-- LV5:phenomexcan_traits_assocs:end -->

<!-- LV5:emerge_traits_assocs:start -->
| Phecode   | Trait description            | Sample size   | Cases   | p-value (adjusted)   |
|:----------|:-----------------------------|:--------------|:--------|:---------------------|
| 241       | Nontoxic nodular goiter      | 47,842        | 3,158   | 8.98e-03             |
| 241.1     | Nontoxic uninodular goiter   | 47,125        | 2,441   | 2.57e-02             |
| 241.2     | Nontoxic multinodular goiter | 46,465        | 1,781   | 4.43e-02             |

Table: Significant trait associations of LV5 in eMERGE. {#tbl:sup:emerge_assocs:lv5}
<!-- LV5:emerge_traits_assocs:end -->


### LV434

![
**Cell types for LV434.**
<!--  -->
<!-- `FIXME:`{.red} create a section for all LVs and clarify how figures were generated, like: -->
<!-- The top samples in human breast cancer cells have larger LV values that were thresholded at 3.0 for visualization purposes. -->
<!--  -->
HEK293 is a cell line derived from human embryonic kidney cells;
3T3 is a cell line derived from mouse embryonic fibroblasts.
](images/lvs_analysis/lv434/lv434-cell_types.svg "Cell types for LV434"){#fig:sup:lv434 width="80%"}

<!-- LV434:phenomexcan_traits_assocs:start -->
| Trait description                        | Sample size   | Cases   | Partition/cluster number   | p-value (adjusted)   |
|:-----------------------------------------|:--------------|:--------|:---------------------------|:---------------------|
| Attention Deficit Hyperactivity Disorder | 53,293        | 19,099  | 29 / 21                    | 7.01e-03             |

Table: Significant trait associations of LV434 in PhenomeXcan. {#tbl:sup:phenomexcan_assocs:lv434}
<!-- LV434:phenomexcan_traits_assocs:end -->

<!-- LV434:emerge_traits_assocs:start -->
| Phecode   | Trait description                        | Sample size   | Cases   | p-value (adjusted)   |
|:----------|:-----------------------------------------|:--------------|:--------|:---------------------|
| 722       | Intervertebral disc disorders            | 47,659        | 7,458   | 6.65e-03             |
| 721       | Spondylosis and allied disorders         | 47,517        | 7,316   | 7.62e-03             |
| 250.4     | Abnormal glucose                         | 45,220        | 4,947   | 1.02e-02             |
| 721.1     | Spondylosis without myelopathy           | 47,315        | 7,114   | 1.22e-02             |
| 720       | Spinal stenosis                          | 44,807        | 4,606   | 1.74e-02             |
| 288       | Diseases of white blood cells            | 47,288        | 2,802   | 2.10e-02             |
| 796       | Elevated prostate specific antigen [PSA] | 51,990        | 2,175   | 3.09e-02             |
| 288.2     | Elevated white blood cell count          | 46,595        | 2,109   | 3.54e-02             |
| 079       | Viral infection                          | 46,991        | 1,934   | 4.19e-02             |

Table: Significant trait associations of LV434 in eMERGE. {#tbl:sup:emerge_assocs:lv434}
<!-- LV434:emerge_traits_assocs:end -->


<!-- ### Top gene modules in the prediction of Niacin as a therapeutic drug

| LV        | Value for Niacin      | Value for atherosclerosis   | Difference   |
|:----------|:----------------------|:----------------------------|:-------------|

Table: Top gene modules/LVs responsible for predicting Niacin as a therapeutic drug for atherosclerosis. {#tbl:sup:emerge_assocs:lv434} -->


### Agreement of consensus clustering partitions with the ensemble by number of clusters

![
**Final selected partitions for follow-up analysis.**
<!--  -->
From all consensus clustering partitions generated with $k$ from 2 to 60, we selected those with a median adjusted Rand index (ARI) with the ensemble members greater the 75th percentile.
](images/clustering/selected_best_partitions_by_k.svg "Consensus partitions agreement with ensemble"){#fig:sup:consensus_agreement width="80%"}
